explore -WSS

explore

author：Wikipedia 2025-09-28 11:02:50 - browse：5

Chris O'Meara/AP

Johnson & Johnson faces a consequential new class action lawsuit — not in its role as a manufacturer of drugs, but as an employer and purchaser of prescription drugs for its workers.

Ann Lewandowski, a health care policy and advocacy director at J&J, sued her company on Monday for allegedly overpaying its pharmacy benefit manager for its employees’ medicines, citing previous STAT reporting to support some of the allegations. Those overpayments, the lawsuit alleges, ultimately come out of workers’ paychecks in the form of high health insurance premiums, higher out-of-pocket drug costs, and stunted wage growth.

In one example, J&J allegedly paid its PBM more than $10,000 for a single 90-day prescription of teriflunomide, a generic medicine for multiple sclerosis, when that same 90-day prescription could be purchased for as little as $30 elsewhere without insurance, according to the lawsuit.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Congenital heart disease patients face new threat of heart failure

explore

WSS

What PEPFAR has meant on the ground in Ukraine

Democratic lawmaker calls for 'well

Pfizer plans to depart BIO

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

Mississippi candidates for statewide offices square off in party primaries

The UK government moves asylum

hotspot

explore

hotspot

How to save PrEP access — and even expand it

Chemotherapy shortages won’t get better under Biden’s latest plan

Walensky prepares to leave CDC — and Congress — behind

Radiology is caught between AI's potential and concern for patients

Medicare details structure of new drug price negotiation program

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Activists slam private health insurers over coverage restrictions

AI models in health care face new federal disclosure requirements

Psychedelics group wrestles with new pharma identity

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

Why workplace violence is so common in health care

What PEPFAR has meant on the ground in Ukraine

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

Patients' immediate access to test results puts radiologists in a bind

Spinal cord stimulation reduces pain in amputees, study finds

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

focus

knowledge

explore

focus